Study of a new drug for acute myeloid leukemia and related blood cancer
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial is testing a new medicine called AMX-883 for people with a type of blood cancer called acute myeloid leukemia (AML) or a high-risk blood disorder called myelodysplastic syndrome (MDS) that has come back or not responded to other treatments. The study hopes to see if the drug is safe and works, either alone or combined with another drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have acute myeloid leukemia (AML) that has come back or not responded to standard treatments, or a high-risk blood disorder (MDS) with a certain percentage of immature cells in the bone marrow.
- You should be generally able to care for yourself (performance status 0-2).
- You need to have finished any previous treatments at least a certain time before starting this study (washout period).
- Your kidney and liver function must be good enough, as determined by blood tests.
- You must not have certain types of leukemia (like APL or CML in blast crisis) or active leukemia in the brain or spinal cord.
- You should not have another active cancer that needed treatment in the last 2 years, or significant heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug, AZD3632, either alone or with other cancer treatments, for people with advanced blood cancers that have specific genetic changes (like KMT2Ar, NPM1m, or others that cause HOX over-expression). The goal is to see if it can help when standard treatments have stopped working.
This trial tests a combination of two medicines (called MA+AZA) for people who have just been diagnosed with acute myeloid leukemia (AML). It aims to see if this treatment can help control the disease and improve outcomes.
This study tests an experimental drug called S241656, either alone or with another medication, for people with certain blood cancers (AML, MDS/AML, or CMML) that haven't responded to standard treatments. The goal is to see if the drug is safe and effective in shrinking or controlling the cancer.
This Phase 1 trial studies CPX-351, a cancer medicine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease relapsed or did not respond to prior treatment. It may help shrink or control the leukemia and improve blood counts in patients who cannot or do not want a stem cell transplant.
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
Hear when a new High Risk Myelodysplastic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.